ENDRA Life Sciences Inc. Stock

$3.58

2.29% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US29273B1044

Symbol

NDRA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

ENDRA Life Sciences Inc. Stock price

$3.58

-35,696.42 99.99% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.08 2.29%

ISIN

US29273B1044

Symbol

NDRA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$2.6m

Enterprise Value

$580.0k

Net debt

$-2.1m

Cash

$2.1m

Shares outstanding

560.0k

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.15

Financial Health

Equity Ratio

57.51%

Return on Equity

-468.68%

ROCE

-365.58%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-9.3m | -

EBIT

$-9.5m

Net Income

$-9.8m | $-8.4m

Free Cash Flow

$-6.6m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

8.73% | -

EBIT

8.23%

Net Income

1.31% | 29.75%

Free Cash Flow

28.77%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-17.52

FCF per Share

$-11.71

Short interest

2.29%

Employees

21.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

ENDRA Life Sciences Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a ENDRA Life Sciences Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a ENDRA Life Sciences Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from ENDRA Life Sciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	6.82 6.82	19% 19% -
- Research and Development Expense	2.68 2.68	42% 42% -
EBITDA	-9.31 -9.31	9% 9% -
- Depreciation and Amortization	0.19 0.19	27% 27% -
EBIT (Operating Income) EBIT	-9.51 -9.51	8% 8% -
Net Profit	-9.77 -9.77	1% 1% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

ENDRA Life Sciences Inc. Stock News

Neutral

Business Wire

●

12 days ago

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS® Liver system against the gold standard, MRI. These findings are ...

Neutral

Business Wire

●

about one month ago

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company...

Neutral

Business Wire

●

3 months ago

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunc...

More ENDRA Life Sciences Inc. News

Company Profile

ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

Head office	United States
CEO	Alexander Tokman
Employees	21
Founded	2007
Website	www.endrainc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now